Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | IGM-2644 |
| Synonyms | |
| Therapy Description |
IGM-2644 is a bispecific IgM T cell engager that targets CD38 and CD3, potentially resulting in complement-dependent cytotoxicity against tumor cells and inhibition of tumor growth (Blood (2022) 140 (Supplement 1): 6010-6011). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| IGM-2644 | IGM 2644|IGM2644 | IGM-2644 is a bispecific IgM T cell engager that targets CD38 and CD3, potentially resulting in complement-dependent cytotoxicity against tumor cells and inhibition of tumor growth (Blood (2022) 140 (Supplement 1): 6010-6011). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05908396 | Phase I | IGM-2644 | Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma | Terminated | USA | 0 |